Peptide-Centered Innovation
Peptigenix is a research-driven biotechnology company developing peptide-based therapeutics to address complex, high-burden medical conditions.
Headquartered in Las Vegas, NV, Peptigenix is advancing its lead investigational program, PEPTI-101, focused on the potential treatment of cancer cachexia—a multifactorial condition that significantly impairs quality of life and survival outcomes in patients with advanced cancer.
Our multidisciplinary team brings together expertise in molecular pharmacology, translational immunology, and peptide chemistry. By harnessing both naturally derived and engineered peptide scaffolds, we aim to explore novel mechanisms with therapeutic relevance.
Peptigenix is in the preclinical development stage and is pursuing early engagement with the FDA to inform future clinical planning for PEPTI-101.
Our work is guided by three core principles:
Scientific Rigor
We prioritize robust preclinical research and translational models to support evidence-based development.
Clinical Relevance
We focus on areas where unmet medical needs remain high and current interventions are limited or ineffective.
Regulatory Transparency
We are committed to regulatory dialogue early in the development process to ensure adherence to FDA and international standards.
